solute carrier family 36 member 2Genealiases: PAT2 · TRAMD1
Q-omics provides the consensus-scored SLC36A2 profile across patient tissues and cancer cell-line models. SLC36A2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SLC36A2 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, SLC36A2 RNA expression shows 6,883 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, KIRC, and STAD as cancer lineages where SLC36A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC36A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC36A2 survival associations across molecular data types. SLC36A2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC36A2 RNA expression–survival associations across cancer types. High SLC36A2 expression shows unfavorable associations in UVM, LIHC, MESO and LUSC, but favorable associations in SCLC and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SLC36A2 RNA expression.
This table summarizes SLC36A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC36A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC36A2 shows lower tumor expression in KIRC, KIRP, HNSC, KICH, BRCA and THCA. The KIRC box plot shows higher SLC36A2 RNA expression in normal versus tumor tissue (log2 FC = −3.861, t-test p < 0.001).
This table shows molecular features associated with SLC36A2 in patient tissues and cancer cell lines. In patient samples, SLC36A2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC36A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
